THERMO FISHER SCIENTIFIC INC. (TMO) FY2026 YTD Q2 P&L / Income Statement

2026-01-01 to 2026-06-27

Swipe to see the full flow
THERMO FISHER SCIENTIFIC INC. (TMO) FY2026 YTD Q2 P&L / Income StatementIncome statement for 2026-01-01 through 2026-06-27. View: Business segment (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETLaboratory Products and Biopharma ServicesLife Sciences SolutionsAnalytical InstrumentsSpecialty DiagnosticsTotal revenuesRevenue before reconciliation (calculated)Elimination of intersegment revenuesGross profit (calculated)Cost of revenue (calculated)Cost of revenuesOperating incomeOperating expenses (calculated)Income before income taxesOther income (expense), net (calculated)Net incomeBenefit from/(provision for) income taxesEquity in earnings/(losses) of unconsolidated entitiesRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$24.09 BGross profit (calculated)Gross profit(calculated)$9.31 BTotal revenuesTotal revenues$23.00 BOperating incomeOperating income$3.95 BIncome before income taxesPretax income$3.66 BNet incomeNet income$3.40 BLaboratory Products and Biopharma ServicesLaboratoryProducts andBiopharma Services$12.73 BOperating expenses (calculated)Operating expenses(calculated)$5.36 BBenefit from/(provision for) income taxesBenefitfrom/(provisionfor) income taxes$238.00 MCost of revenue (calculated)Cost of revenue(calculated)$13.69 BOther income (expense), net (calculated)Other income,net (calculated)−$292.00 MLife Sciences SolutionsLife Sciences Solutions$5.45 BEquity in earnings/(losses) of unconsolidated entitiesEquity inearnings/(losses)of unconsolidated…−$23.00 MAnalytical InstrumentsAnalytical Instruments$3.56 BCost of revenuesCost ofrevenues$13.69 BSpecialty DiagnosticsSpecialty Diagnostics$2.35 BElimination of intersegment revenuesElimination ofintersegment revenues−$1.09 B
Chart details

THERMO FISHER SCIENTIFIC INC. (TMO) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-27. View: Business segment (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
22,999,000,000 US dollars
Cost of revenue (calculated)
13,687,000,000 US dollars
Gross profit (calculated)
9,312,000,000 US dollars
Operating expenses (calculated)
5,362,000,000 US dollars
Operating income
3,950,000,000 US dollars
Other income (expense), net (calculated)
negative 292,000,000 US dollars
Income before income taxes
3,658,000,000 US dollars
Benefit from/(provision for) income taxes
238,000,000 US dollars
Net income
3,397,000,000 US dollars
Life Sciences Solutions
5,450,000,000 US dollars
Analytical Instruments
3,563,000,000 US dollars
Specialty Diagnostics
2,346,000,000 US dollars
Laboratory Products and Biopharma Services
12,729,000,000 US dollars
Cost of revenues
13,687,000,000 US dollars
Selling, general and administrative expenses
4,514,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Research and development expenses
700,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Restructuring and other costs
147,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Revenue before reconciliation (calculated)
24,088,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Elimination of intersegment revenues
negative 1,089,000,000 US dollars. Reported reconciliation to consolidated revenue.
Equity in earnings/(losses) of unconsolidated entities
negative 23,000,000 US dollars. Reported below-tax contribution to net income.
Life Sciences Solutions costs (calculated)
3,456,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Analytical Instruments costs (calculated)
2,784,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Specialty Diagnostics costs (calculated)
1,700,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Laboratory Products and Biopharma Services costs (calculated)
11,015,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.
Reconciling items (calculated)
94,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
  • Of which attributable to THERMO FISHER SCIENTIFIC INC.: $3.39 B; to noncontrolling interests: $10.00 M.
THERMO FISHER SCIENTIFIC INC. (TMO) FY2026 YTD Q2 Revenue by Business Segment (5 categories) Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

40.5%

Gross profit / revenue

Operating margin

17.2%

Operating profit / revenue

Cash conversion

97.6%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!